chr5-251439-C-T
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM5PP3_StrongPP5_Very_Strong
The NM_004168.4(SDHA):c.1765C>T(p.Arg589Trp) variant causes a missense change. The variant allele was found at a frequency of 0.0000136 in 1,613,864 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R589Q) has been classified as Likely pathogenic.
Frequency
Consequence
NM_004168.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SDHA | NM_004168.4 | c.1765C>T | p.Arg589Trp | missense_variant | 13/15 | ENST00000264932.11 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SDHA | ENST00000264932.11 | c.1765C>T | p.Arg589Trp | missense_variant | 13/15 | 1 | NM_004168.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152206Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000120 AC: 3AN: 251004Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135690
GnomAD4 exome AF: 0.0000137 AC: 20AN: 1461658Hom.: 0 Cov.: 32 AF XY: 0.0000124 AC XY: 9AN XY: 727140
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152206Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74374
ClinVar
Submissions by phenotype
Paragangliomas 5 Pathogenic:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 01, 2010 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | KCCC/NGS Laboratory, Kuwait Cancer Control Center | Sep 13, 2023 | This variant is present in population databases (rs387906780, gnomAD 0.007%). This missense change has been observed in individuals with paraganglioma or gastrointestinal stromal tumors (PMID: 20484225, 22955521, 25405498, 28546994). ClinVar contains an entry for this variant (Variation ID: 30132). Experimental studies have shown that this missense change affects SDHA function (PMID: 20484225, 21505157, 23043141). This variant disrupts the p.Arg589 amino acid residue in SDHA. Other variant(s) that disrupt this residue have been observed in individuals with SDHA-related conditions (PMID: 23612575, 28546994), which suggests that this may be a clinically significant amino acid residue. Therefore, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Feb 08, 2024 | This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 27847310]. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 20484225, 28070496, 30949620]. - |
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 06, 2022 | Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies suggest a damaging effect: absent SDH activity and reduced protein expression (Burnichon et al., 2010); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 28798025, 23043141, 21505157, 23154507, 19628817, 34014604, 22955521, 29978154, 28546994, 25405498, 20484225) - |
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2023 | SDHA: PS3, PM1, PM5, PP3, BP1 - |
Paragangliomas 5;C5700310:Mitochondrial complex II deficiency, nuclear type 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 16, 2023 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 589 of the SDHA protein (p.Arg589Trp). This variant is present in population databases (rs387906780, gnomAD 0.007%). This missense change has been observed in individuals with paraganglioma or gastrointestinal stromal tumors (PMID: 20484225, 22955521, 25405498, 28546994). ClinVar contains an entry for this variant (Variation ID: 30132). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SDHA protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects SDHA function (PMID: 20484225, 21505157, 23043141). This variant disrupts the p.Arg589 amino acid residue in SDHA. Other variant(s) that disrupt this residue have been observed in individuals with SDHA-related conditions (PMID: 23612575, 28546994), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. - |
Dilated cardiomyopathy 1GG Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 26, 2024 | - - |
Gastrointestinal stromal tumor Pathogenic:1
Likely pathogenic, criteria provided, single submitter | research | “Giorgio Prodi” Cancer Research Center, University of Bologna | Oct 01, 2021 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 11, 2022 | The p.R589W pathogenic mutation (also known as c.1765C>T), located in coding exon 13 of the SDHA gene, results from a C to T substitution at nucleotide position 1765. The arginine at codon 589 is replaced by tryptophan, an amino acid with dissimilar properties. This mutation has been detected in individuals with paraganglioma or gastrointestinal stromal tumor (Burnichon N et al. Hum. Mol. Genet., 2010 Aug;19:3011-20; Casey RT et al. Mol Genet Genomic Med, 2017 May;5:237-250; Ambry internal data). This alteration was also reported in gastrointestinal stromal tumor tissues (Pantaleo MA et al. J. Natl. Cancer Inst., 2011 Jun;103:983-7; Wagner AJ et al. Mod. Pathol., 2013 Feb;26:289-94). Several functional studies indicate that this mutation impairs succinate dehydrogenase activity and likely interferes with SDHAF2 binding which is essential for FAD insertion into SDHA (Hao HX et al. Science, 2009 Aug;325:1139-42; Burnichon N et al. Hum. Mol. Genet., 2010 Aug;19:3011-20; Kim HJ et al. J. Biol. Chem., 2012 Nov;287:40670-9; Huang S et al. Plant Signal Behav, 2013 Feb;8:e22815; Lorendeau D et al. Metab. Eng., 2017 09;43:187-197). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at